GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Ebos Group Ltd (OTCPK:EBOSF) » Definitions » Debt-to-EBITDA

Ebos Group (Ebos Group) Debt-to-EBITDA : 3.07 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Ebos Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ebos Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $152 Mil. Ebos Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,077 Mil. Ebos Group's annualized EBITDA for the quarter that ended in Dec. 2023 was $401 Mil. Ebos Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 3.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ebos Group's Debt-to-EBITDA or its related term are showing as below:

EBOSF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.61   Med: 2.27   Max: 4.12
Current: 3.14

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ebos Group was 4.12. The lowest was 1.61. And the median was 2.27.

EBOSF's Debt-to-EBITDA is ranked worse than
61.33% of 75 companies
in the Medical Distribution industry
Industry Median: 1.87 vs EBOSF: 3.14

Ebos Group Debt-to-EBITDA Historical Data

The historical data trend for Ebos Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ebos Group Debt-to-EBITDA Chart

Ebos Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.11 2.48 1.91 4.12 2.27

Ebos Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.34 3.89 2.38 2.27 3.07

Competitive Comparison of Ebos Group's Debt-to-EBITDA

For the Medical Distribution subindustry, Ebos Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ebos Group's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Ebos Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ebos Group's Debt-to-EBITDA falls into.



Ebos Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ebos Group's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(61.601 + 794.947) / 377.901
=2.27

Ebos Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(152.477 + 1077.256) / 401.254
=3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Ebos Group  (OTCPK:EBOSF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ebos Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ebos Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ebos Group (Ebos Group) Business Description

Traded in Other Exchanges
Address
108 Wrights Road, P.O. Box 411, Christchurch, STL, NZL, 8024
Ebos is the largest pharmaceutical wholesaler and distributor across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 60% and 30% of revenue respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low single digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.

Ebos Group (Ebos Group) Headlines

From GuruFocus

Half Year 2024 EBOS Group Ltd Earnings Call Transcript

By GuruFocus Research 02-28-2024